Jonathan S. Berek
Publication Details
-
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
J Clin Oncol. 2009; (3): 418-25
This phase III study tested the hypothesis that the CA-125-specific murine monoclonal antibody, oregovomab, administered as a monoimmunotherapy after front-line therapy in a selected ovarian cancer population would prolong time to relapse (TTR) and, ultimately, survival.
Help